Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

Eli Lilly and Company (NYSE: LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen receptor ...

Santander issues warning as thousands of customers lose £227 each — and most victims are women

Santander’s research revealed a third of scams took place on Facebook, followed by a quarter on Instagram, alongside a ...